High mutation detection rates in cerebral cavernous malformation upon stringent inclusion criteria: one‐third of probands are minors. Issue 2 (14th January 2014)

• Record Type: Journal Article
• Authors: Spiegler, Stefanie; Najm, Juliane; Liu, Jian; Gkalympoudis, Stephanie; Schröder, Winnie; Borck, Guntram; Brockmann, Knut; Elbracht, Miriam; Fauth, Christine; Ferbert, Andreas; Freudenberg, Leonie; Grasshoff, Ute; Hellenbroich, Yorck; Henn, Wolfram; Hoffjan, Sabine; Hüning, Irina; Korenke, G. Christoph; Kroisel, Peter M.; Kunstmann, Erdmute; Mair, Martina; Munk‐Schulenburg, Susanne; Nikoubashman, Omid; Pauli, Silke; Rudnik‐Schöneborn, Sabine; Sudholt, Irene; Sure, Ulrich; Tinschert, Sigrid; Wiednig, Michaela; Zoll, Barbara; Ginsberg, Mark H.; Felbor, Ute;
• Is Part Of: Molecular genetics & genomic medicine. Volume 2:Issue 2(2014:Mar.)
• Page Start: 176
• Page End: 185
• Publication Date: 2014-01-14
• Subjects: Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.60
• Languages: English
• ISSNs: 2324-9269

Abstract

<abstract abstract-type="main" id="mgg360-abs-0001"> <title>Abstract</title> <p>Cerebral cavernous malformations (CCM) are prevalent vascular malformations occurring in familial autosomal dominantly inherited or isolated forms. Once CCM are diagnosed by magnetic resonance imaging, the indication for genetic testing requires either a positive family history of cavernous lesions or clinical symptoms such as chronic headaches, epilepsy, neurological deficits, and hemorrhagic stroke or the occurrence of multiple lesions in an isolated case. Following these inclusion criteria, the mutation detection rates in a consecutive series of 105 probands were 87% for familial and 57% for isolated cases. Thirty‐one novel mutations were identified with a slight shift towards proportionally more <italic>CCM3</italic> mutations carriers than previously published (<italic>CCM1</italic>: 60%, <italic>CCM2</italic>: 18%, <italic>CCM3</italic>: 22%). In‐frame deletions and exonic missense variants requiring functional analyses to establish their pathogenicity were rare: An in‐frame deletion within the C‐terminal FERM domain of CCM1 resulted in decreased protein expression and impaired binding to the transmembrane protein heart of glass (HEG1). Notably, 20% of index cases carrying a <italic>CCM</italic> mutation were below age 10 and 33% below age 18 when referred for genetic testing. Since fulminant disease courses during the first years of life were observed in <italic>CCM1</italic> and <italic>CCM3</italic> mutation carriers, predictive testing of minor siblings became an issue.</p> </abstract>